Fennec Pharmaceuticals (FENC) CEO gets 1,159-share award

Rhea-AI Filing Summary

Fennec Pharmaceuticals Chief Executive Officer Jeffrey S. Hackman acquired 1,159 Common Shares on July 31, 2026 through the release of restrictions on shares originally awarded on March 28, 2025. Following this equity compensation event, his direct holdings total 65,143 Common Shares at a reported transaction price of $0.0000 per share.

Insider Trade Summary

Net Buyer: 1,159 shares

Net Buy 1 txn

Insider Hackman Jeffrey S.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	1,159	$0.00	$0.00

Holdings After Transaction: Common Shares — 65,143 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Shares acquired: 1,159 Common Shares Transaction price: $0.0000 per share Direct holdings after transaction: 65,143 Common Shares

3 metrics

Shares acquired 1,159 Common Shares Grant, award, or other acquisition on July 31, 2026

Transaction price $0.0000 per share Reported price for the 1,159 Common Shares acquired as equity compensation

Direct holdings after transaction 65,143 Common Shares Total Common Shares directly owned by CEO Jeffrey S. Hackman after the award

Key Terms

Common Shares, Grant, award, or other acquisition, released from restriction

3 terms

Common Shares financial

"security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 04:06 PM Accepted by SEC EDGAR 08/03/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider share transaction did Fennec Pharmaceuticals (FENC) report for CEO Jeffrey Hackman?

CEO Jeffrey S. Hackman acquired 1,159 Common Shares of Fennec Pharmaceuticals on July 31, 2026. The shares reflect the release of restrictions from an equity award originally granted on March 28, 2025, and were reported at a transaction price of $0.0000 per share.

How many FENC shares does CEO Jeffrey Hackman directly hold after the July 31, 2026 transaction?

After the July 31, 2026 transaction, CEO Jeffrey S. Hackman directly holds 65,143 Common Shares of Fennec Pharmaceuticals. This total includes the 1,159 shares that became unrestricted from a prior equity award granted on March 28, 2025.

What was the price per share for the 1,159 Fennec (FENC) shares acquired by the CEO?

The 1,159 Common Shares acquired by CEO Jeffrey S. Hackman were reported at a price of $0.0000 per share. This indicates the shares were received as part of equity compensation rather than purchased in the open market for cash consideration.

What is the nature of the 1,159 FENC shares reported for CEO Jeffrey Hackman?

The 1,159 shares represent shares released from restriction from Common Shares originally awarded on March 28, 2025. The transaction reflects vesting or lapse of restrictions on a prior equity grant, not a new market purchase or sale.

Was the Fennec (FENC) CEO’s July 31, 2026 share acquisition made under a Rule 10b5-1 trading plan?

The report’s Rule 10b5-1 checkbox is unchecked, and there is no footnote indicating a trading plan. Based on this disclosure, the 1,159-share acquisition is not identified as executed pursuant to a Rule 10b5-1 pre-arranged trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hackman Jeffrey S.

(Last) (First) (Middle)

68 TW ALEXANDER DRIVE

PO BOX 13628

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	07/31/2026		A		1,159	A	$0	65,143	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Jeffrey Hackman	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)